Skip to main content

2021

2021-12-23
The Medical Products Agency in Sweden has agreed to be reference member state for Moberg Pharma AB’s registration application for MOB-015 (nail fungus treatment). The company will submit the registration application in Europe through the decentralized process, and market approval is expected in 2023.
2021-12-06
Peter Wolpert, Chairman of the Board since 2019 of Moberg Pharma AB (publ), has informed the Nomination Committee that he has been appointed CEO of Industrifonden starting from March 2022. Peter will complete his current term as chairman of the board but will not be available for reelection at the Annual General Meeting in May 2022.
2021-11-09
APPROVAL FROM THE EMA´s PEADIATRIC COMMITTEE 
2021-11-08
Moberg Pharma AB (OMX: MOB) has entered into a collaboration with Allderma AB for the launch of MOB-015 (for nail fungus) in Sweden, Norway and Denmark. Allderma is managed by the commercial leaders which were responsible for the successful Nordic launch of Nalox[®], Moberg Pharma’s first-generation nail fungus product.
2021-10-22
STOCKHOLM, October 22[nd], 2021 – In accordance with the resolution of the Annual General Meeting on May 18[th], 2021, the Chairman of the Board has contacted the company’s three largest shareholders or group of shareholders in terms of votes to form a Nomination Committee. These shareholders have been invited to appoint one representative each who, together with the Chairman of the Board, will comprise the Nomination Committee. As not all of the company’s three largest shareholders or group of shareholders have wished to appoint such representative, the fourth largest shareholder/group of shareholders have been invited to appoint one representative and so on until the Nomination Committee now comprises of four members, in accordance with the resolution of the Annual General Meeting on May 18[th], 2021.
2021-09-22
Moberg Pharma AB (OMX: MOB) today announces that it has received approval of the pediatric plan for MOB-015 from EMA’s paediatric committee (PDCO). This approval enables the company to pursue a full marketing authorization application providing up to ten years of exclusivity in Europe following approval. The company´s timeline remains, with planned submission for MOB-015 in Europe this year and expected market approval in 2023.
2021-08-10
REGISTRATION PREPARATIONS FULLY UNDERWAY
2021-07-30
STOCKHOLM, July 30[th], 2021, Moberg Pharma AB (OMX: MOB) announced that the total number of common shares in the company has increased to 45,511,425. The 910,000 newly issued shares are held by the company to secure its commitments under incentive programmes.
2021-06-23
STOCKHOLM, June 23[th], 2021, Moberg Pharma AB (OMX: MOB) announces the appointment of Agneta Larhed as Vice President Pharmaceutical Innovation & Development of Moberg Pharma. Dr Larhed will be joining the management team at Moberg Pharma in September.
2021-05-18
STOCKHOLM, May 18[th], 2021. Moberg Pharma AB (publ)’s (“Moberg Pharma” or the “Company”) Annual General Meeting took place today. The Annual General Meeting resolved in accordance with the Nomination Committee’s and Board of Directors’ proposals as set out below.
2021-05-11
REGISTRATION PREPARATIONS FULLY UNDERWAY 
2021-04-19
Shareholders in Moberg Pharma AB (publ) (reg. no. 556697-7426) (the “Company”) are hereby convened to the Annual General Meeting on Tuesday, 18 May 2021.
2021-02-09
Financing for both MOB-015 and BUPI